How did the COVID-19 pandemic affect Intuitive Surgical's revenue in Q3 2020?

The COVID-19 pandemic negatively impacted Intuitive Surgical's Q3 2020 revenue, leading to a 4% decrease year-over-year to $1,077.7 million. This was primarily due to a significant decline in systems revenue (-21%) as hospitals deferred capital expenditure decisions. However, procedure volumes and instrument/accessory revenue showed resilience, with procedures increasing by 7% and instruments/accessories revenue up by 4%.

What is the company doing to support its customers during the pandemic?

Intuitive Surgical implemented a 'Customer Relief Program' which included service fee credits based on system under-utilization and deferred payment terms for leases and other receivables. These measures provided financial relief but also contributed to a decrease in service revenue.

How is the installed base of da Vinci Surgical Systems performing?

The installed base of da Vinci Surgical Systems continued to grow, increasing by approximately 8% to 5,865 systems as of September 30, 2020, compared to the prior year. This growth in installed base is a key indicator for future recurring revenue from instruments, accessories, and services.

What is the outlook for system placements?

The company anticipates that system placements will lag behind the recovery of procedure volumes due to the ongoing impact of the COVID-19 pandemic. Hospitals are expected to utilize existing system capacity before purchasing new ones, leading to an expectation of lower year-over-year system placements for the remainder of 2020.

ISRG 10-Q Quarterly Report Q3 FY2020 — Revenue, Net Income, EPS

Summary

Intuitive Surgical, Inc. (ISRG) reported its third-quarter 2020 financial results, reflecting the ongoing impact of the COVID-19 pandemic on its operations. Total revenue for the quarter decreased by 4% year-over-year to $1,077.7 million. This decline was primarily driven by a 21% decrease in systems revenue, stemming from a 29% drop in system shipments, as hospitals continued to defer capital expenditures. Despite the headwinds, the company saw a 7% increase in da Vinci procedures performed during the quarter, reaching approximately 329,000, and instruments and accessories revenue saw a 4% increase. This indicates resilience in procedure volume and recurring revenue streams, even as system sales were affected. The company also highlighted its Customer Relief Program, which provided service fee credits and payment deferrals to customers, impacting service revenue. Looking ahead, management anticipates continued uncertainty regarding system placements and procedure volumes due to the pandemic's evolving nature.

Financial Highlights

47 data points

Beta

Revenue

$1.08B

0.7% Gross Margin

Net Income

$313.90M

0.3% Net Margin

EPS (Diluted)

$2.60

Total Assets

$10.62B

Cash & Equivalents

$1.37B

Free Cash Flow

$274.60M

Financial Statements

Beta

Revenue	$1.08B
Cost of Revenue	$353.40M
Gross Profit	$724.30M
R&D Expenses	$155.00M
SG&A Expenses	$298.90M
Operating Expenses	$453.90M
Operating Income	$270.40M
Net Income	$313.90M
EPS (Basic)	$2.68
EPS (Diluted)	$2.60
Shares Outstanding (Basic)	352.00M
Shares Outstanding (Diluted)	361.90M

Key Highlights

1Total revenue for Q3 2020 decreased by 4% to $1,077.7 million, impacted by the COVID-19 pandemic.
2Systems revenue saw a significant decrease of 21% to $267.8 million due to a 29% decline in da Vinci Surgical System shipments.
3Instruments and accessories revenue increased by 4% to $630.6 million, supported by a 7% rise in da Vinci procedures performed (329,000 in Q3 2020).
4Service revenue decreased by 2% to $179.3 million, partly due to customer relief programs.
5The da Vinci Surgical System installed base grew by 8% to approximately 5,865 systems as of September 30, 2020.
6The company ended the quarter with a strong cash position of $6.4 billion in cash, cash equivalents, and investments.
7The company explicitly noted the impact of COVID-19 on its business, leading to deferred system purchase decisions and potential disruption to procedure volumes.

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions